This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ABSTRACT: For the full year 2002, the top ten biotechnology houses generated combined revenues (= royalties/licensing income + ethical or product sales; product sales includes both diagnostic and prescription drugs) of US$15.9bn, a 27 per cent increase over 2001. Using Datamonitor's proprietary forecasting methodology, the ethical sales of the ten leading biotechnology companies (Amgen, Genentech, Serono, Genzyme, Biogen, Chiron, MedImmune, Gilead, IDEC and Celltech) are forecast to grow from US$17...
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
For more information, see the Journal of Commercial Biotechnology website
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents
Drug Patent Expirations for April 24 2013
DrugPatentWatch Serves Your Competitive Intelligence Needs
Subscribers have access to valuable datasets, including: